VR technology that transforms the discovery of COVID-19 drugs

Virtual reality (VR) is not a new technology. The term dates back to the 1980s, when researchers first developed technology and gear, and a few years later, young people like Nanome CEO and co-founder Steve McCloskey had a first taste of virtual reality. in the fun areas of amusement parks or playing video games at home.

It is advancing rapidly until 2021, where virtual reality and its applications have evolved far beyond entertainment. McCloskey spoke with Outsourcing-Pharma about how Nanome’s team works with researchers at the Oak Ridge National Laboratory and other reputable institutions to leverage VR technology to analyze the COVID-19 virus, discover drugs, and more.

OSP: Could you talk a little bit about your relationship and experience with VR technology?

SM: In fact, I tried virtual reality in the 1990s at Six Flags in Los Angeles when he was little. Initially, while I was going through my nanoengineering curriculum at the University of California at San Diego, I thought there should be a better way to visualize molecular systems than traditional 2D representations (e.g., the structures of nanoengineering). Lewis points).

Growing up with video games, I thought that video game graphics engines could be reused for molecular visualizations. Around the same time, in 2014/15, just after Facebook acquired Oculus, that’s when it all clicked.

Keita, our chief operating officer and co-founder, came from a background in film / media and computer science. When he tested the Google Cardboard headphones in 2015, he clicked that it had to be the next computer interface and that there had to be better use cases than zombie shooters and roller coasters. We later met at a VR film festival at UC San Diego in 2015 and formed a company shortly thereafter.

Source link

Leave a Comment

Your email address will not be published.